6.85
+0.635(+10.23%)
Currency In USD
| Previous Close | 6.21 |
| Open | 6.41 |
| Day High | 7.12 |
| Day Low | 6.17 |
| 52-Week High | 22.9 |
| 52-Week Low | 5.34 |
| Volume | 83,371 |
| Average Volume | 55,865 |
| Market Cap | 16M |
| PE | -0.78 |
| EPS | -8.72 |
| Moving Average 50 Days | 7.75 |
| Moving Average 200 Days | 11.62 |
| Change | 0.64 |
If you invested $1000 in Cadrenal Therapeutics, Inc. Common Stock (CVKD) since IPO date, it would be worth $110.76 as of February 22, 2026 at a share price of $6.845. Whereas If you bought $1000 worth of Cadrenal Therapeutics, Inc. Common Stock (CVKD) shares 2 years ago, it would be worth $622.27 as of February 22, 2026 at a share price of $6.845.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor
GlobeNewswire Inc.
Jan 12, 2026 1:00 PM GMT
Company to also participate in Fireside Chat at Lytham Partners 2026 Investor Healthcare Summit on Thursday, January 15, 2026SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company de
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
GlobeNewswire Inc.
Dec 17, 2025 2:00 PM GMT
PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced that
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
GlobeNewswire Inc.
Dec 11, 2025 1:05 PM GMT
Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan